DE60038680D1 - Antisense-therapie für hormonregulierte tumoren - Google Patents

Antisense-therapie für hormonregulierte tumoren

Info

Publication number
DE60038680D1
DE60038680D1 DE60038680T DE60038680T DE60038680D1 DE 60038680 D1 DE60038680 D1 DE 60038680D1 DE 60038680 T DE60038680 T DE 60038680T DE 60038680 T DE60038680 T DE 60038680T DE 60038680 D1 DE60038680 D1 DE 60038680D1
Authority
DE
Germany
Prior art keywords
tumors
seq
odn
igfbp
mammals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60038680T
Other languages
English (en)
Other versions
DE60038680T2 (de
Inventor
Martin Gleave
Hideaki Miyake
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Publication of DE60038680D1 publication Critical patent/DE60038680D1/de
Application granted granted Critical
Publication of DE60038680T2 publication Critical patent/DE60038680T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60038680T 1999-07-19 2000-07-19 Antisense-therapie für hormonregulierte tumoren Expired - Lifetime DE60038680T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14449599P 1999-07-19 1999-07-19
US144495P 1999-07-19
PCT/CA2000/000853 WO2001005435A2 (en) 1999-07-19 2000-07-19 Antisense therapy for hormone-regulated tumors

Publications (2)

Publication Number Publication Date
DE60038680D1 true DE60038680D1 (de) 2008-06-05
DE60038680T2 DE60038680T2 (de) 2009-05-07

Family

ID=22508861

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60038680T Expired - Lifetime DE60038680T2 (de) 1999-07-19 2000-07-19 Antisense-therapie für hormonregulierte tumoren

Country Status (13)

Country Link
US (1) US7297684B1 (de)
EP (1) EP1200579B1 (de)
JP (1) JP5121106B2 (de)
KR (2) KR100779752B1 (de)
AT (1) ATE393220T1 (de)
AU (1) AU772480B2 (de)
CA (1) CA2375467C (de)
DE (1) DE60038680T2 (de)
HU (1) HU228465B1 (de)
IL (2) IL146565A0 (de)
NO (1) NO332388B1 (de)
NZ (1) NZ516701A (de)
WO (1) WO2001005435A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR633101A0 (en) * 2001-07-13 2001-08-02 University Of Sydney, The Method
NZ577565A (en) * 2001-10-09 2010-10-29 Isis Pharmaceuticals Inc Antisense modulation of insulin-like growth factor binding protein 5 expressions
US6750019B2 (en) * 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
AU2003237616B2 (en) 2002-01-17 2007-07-05 The University Of British Columbia Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
KR101117673B1 (ko) 2002-08-21 2012-03-07 더 유니버시티 오브 브리티쉬 콜롬비아 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
ES2345330T3 (es) 2002-10-02 2010-09-21 The University Of British Columbia Oligonucleotidos para el tratamiento del cancer de prostata y otros canceres.
US8722872B2 (en) 2002-10-02 2014-05-13 The University Of British Columbia Compositions and methods for treatment of prostate and other cancers
WO2005030260A1 (en) * 2003-10-01 2005-04-07 The University Of British Columbia Bispecific oligonucleotide for the treatment of cns malignancies
PT2444505T (pt) * 2004-07-23 2017-01-13 Pacific Edge Ltd Marcadores urinários para a deteção de cancro da bexiga
WO2008106781A1 (en) 2007-03-05 2008-09-12 The University Of British Columbia Treatment of squamous cell carcinoma with hsp27 antisense oligonucleotides and radiotherapy
JP5390179B2 (ja) * 2008-12-24 2014-01-15 花王株式会社 Igfbp−5発現抑制剤
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2090702A1 (en) 1990-08-28 1992-03-01 Michael C. Kiefer Insulin-like growth factor binding protein igfbp-5
JPH06503947A (ja) 1990-08-28 1994-05-12 カイロン コーポレイション Igfbp―5をコードする遺伝物質
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US6750019B2 (en) 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression

Also Published As

Publication number Publication date
HUP0201868A2 (en) 2002-12-28
DE60038680T2 (de) 2009-05-07
KR100856475B1 (ko) 2008-09-08
NZ516701A (en) 2004-11-26
KR20070036180A (ko) 2007-04-02
US7297684B1 (en) 2007-11-20
JP5121106B2 (ja) 2013-01-16
NO332388B1 (no) 2012-09-10
WO2001005435A2 (en) 2001-01-25
KR100779752B1 (ko) 2007-11-27
CA2375467C (en) 2013-10-29
IL146565A0 (en) 2002-07-25
HU228465B1 (en) 2013-03-28
ATE393220T1 (de) 2008-05-15
EP1200579B1 (de) 2008-04-23
AU6144500A (en) 2001-02-05
IL146565A (en) 2012-02-29
WO2001005435A3 (en) 2001-03-22
CA2375467A1 (en) 2001-01-25
NO20020259D0 (no) 2002-01-17
KR20020033735A (ko) 2002-05-07
EP1200579A2 (de) 2002-05-02
JP2003504418A (ja) 2003-02-04
NO20020259L (no) 2002-01-17
AU772480B2 (en) 2004-04-29

Similar Documents

Publication Publication Date Title
ATE393220T1 (de) Antisense-therapie für hormonregulierte tumoren
NO20014058D0 (no) TRPM-2 antisense-terapi
RO93650B (ro) Procedeu pentru obtinerea unei polipeptide umane fiziologic activa
MY134810A (en) Targeted gene expression of thrombopoietein, dnase i and b-interferon
CA2046916A1 (en) Methods and compositions for treatment of cancer using oligonucleotides
DK0928335T3 (da) Fremgangsmåde til anvendelse af oligonukleotider med modificerede CpG-dinukleosider
EP0702563A4 (de) Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
WO2003090512A3 (en) Regeneration of endogenous myocardial tissue by induction of neovascularization
AU2001287639A1 (en) Trp8, trp9 and trp10, markers for cancer
HK1082379A1 (en) Therapeutic retroviral vectors for gene therapy
AU688101B2 (en) Live vaccine for the treatment of tumour diseases
GB9323008D0 (en) Improvements relating to cancer therapy
DE60144525D1 (de) Des protein (igfbp)-2-oligodeoxynukleotide zur behandlung von prostatakrebs
BR9912279A (pt) Uso de uteroglobina humana recombinante no tratamento de condições inflamatórias e fibróticas
HUT64569A (en) A process for preparing polypeptide-type compounds usefules for medical treatment of the human body
EP1070122A4 (de) Induktion apoptischer oder zytotoxischer genexpression durch adenovirus-vermittelten gen-kotransfer
HUP0104046A2 (hu) Adenovírus-közvetített génterápia
AU6349400A (en) Methods for treatment of hyperproliferative diseases using human mda-7
ATE552887T1 (de) Tumorspezifischer vektor für die gentherapie
WO2001087039A3 (en) Treatment of neoplasia / transformation using pituitary tumor transforming gene 2
NZ502270A (en) Derivatives of mammalian secretory peptide-9 for treating cancer and may be used in conjunction with cytokines
AU4935600A (en) New vaccine formulations - 2
EP1346045A4 (de) Menschliches protoonkogen und darin codiertes protein
Sikora et al. Genetic drug activation strategies for breast cancer
Luster et al. Modification of tumor cell proliferation and peptide hormone secretion

Legal Events

Date Code Title Description
8364 No opposition during term of opposition